THMO צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Cesca Therapeutics

ThermoGenesis is implementing advanced biobanking and stem cell processing methods. A closed ecosystem featuring proprietary cartridges and FDA protection ensures high B2B customer loyalty. The quarterly EPS trend reflects the result of this synergy, with the current figure standing at 87.90. However, a prolonged liquidity shortage and uncertainty regarding the long-term course create challenges for management in monetizing software.

To find a balance between asset cost and quality, evaluate the net income per share trend, which eliminates manipulative distortions and reveals real operational efficiency through the daily recording of quarterly changes. In the case of ThermoGenesis (THMO), this quarterly net income per share growth metric reflects the conversion of the installed equipment base into a stable cash flow from the sale of consumables.